Janssen-Cilag International NV Release: New Marketing Authorisation Application Submitted to European Medicines Agency for Ibrutinib for the Treatment of Two Forms of Blood Cancer
Published: Oct 30, 2013
BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Help employers find you! Check out all the jobs and post your resume.